John Vandermosten talks about the expansion of gene therapy and how it is used to combat auto-immune...
Senior Biotechnology Research Analyst
Zacks Investment Research
John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small-cap biotechnology names. His background includes 17 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. Formerly, Mr. Vandermosten was a research analyst for Singular Research covering the healthcare space and a consultant with Coker Group, a national healthcare services firm providing financial advisory, investment banking, healthcare IT, and other services to hospitals and other health care organizations.
Content from John Vandermosten
John Vandermosten digs into the biotechnology sector. Learn the smoking cessation drugs likely to cr...
John moderated a panel of Biotech CEOs earlier this week (October 1st) at the MicroCap Conference in...